Johnson & Johnson $JNJ Shares Bought by Relyea Zuckerberg Hanson LLC

Relyea Zuckerberg Hanson LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 11.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,504 shares of the company’s stock after buying an additional 3,259 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Johnson & Johnson were worth $5,841,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the period. United Bank grew its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Scientech Research LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth approximately $954,000. UniSuper Management Pty Ltd raised its position in Johnson & Johnson by 1.8% in the 1st quarter. UniSuper Management Pty Ltd now owns 416,098 shares of the company’s stock valued at $69,006,000 after purchasing an additional 7,326 shares during the last quarter. Finally, Teewinot Capital Advisers L.L.C. acquired a new stake in Johnson & Johnson during the 1st quarter worth $35,166,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. Barclays lifted their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Finally, Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $211.25.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $207.26 on Monday. The stock’s 50 day moving average price is $201.17 and its 200 day moving average price is $183.07. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a market cap of $499.35 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.